About Us
At Ikena®, we are defined by our ever-evolving science and our unwavering commitment to patients.
Our Company
Leadership
Board of Directors
Owen Hughes
Chairman
David Bonita, M.D.
DIRECTOR
Iain D. Dukes, D. Phil.
DIRECTOR
Jean-François Formela, M.D.
DIRECTOR
Mark Manfredi, Ph.D.
PRESIDENT AND CHIEF EXECUTIVE OFFICER
Maria Koehler, M.D., Ph.D.
DIRECTOR
Otello Stampacchia, Ph.D.
DIRECTOR
Richard Wooster, Ph.D.
DIRECTOR
Scientific Advisory Board
Partnering
Our Business Development team works hand in hand with our Research and Development team to thoughtfully identify prospective external opportunities that are aligned with Ikena’s mission. We also actively seek discovery, development, and commercialization partners, with the goal of accelerating the advancement of our novel targeted oncology therapies.
Bristol Myers Squibb Partnership
In January 2019, Ikena announced an exclusive global strategic collaboration with Celgene Corporation, now Bristol Myers Squibb, for the development of two of Ikena’s pipeline programs; the aryl hydrocarbon receptor (AHR) antagonist program and the kynurenine-degrading enzyme (“Kynase”) program. Under the terms of the agreement, Ikena received an upfront payment of $95.0 million, which consisted of $80.5 million in cash and an equity investment of approximately $14.5 million.
Merck Partnership
Get in touch with us to partner
Ikena collaborates with leading academic institutions and biopharmaceutical companies to enhance our biomarker-driven discovery and development efforts. If you have a proposal or interest in a partnership, please send us an email or use the contact form linked below to briefly describe your project.
